Anahit Blikian, MD
Adolescent Medicine · Glendale, CANPI 1376596403
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 234 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 28 manufacturers reported payments, led by Amgen at 27.1% of the total. Among adolescent medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 234 payments — averaging $23.33 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$1K
- Amarin Pharma, Inc.$736
- Novo Nordisk$464
- Sanofi-aventis U.S. LLC$451
- Lilly USA, LLC$305
- Merck$293
- plus $2K from 22 others
What the payments were for
- Food & beverage$5,459100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 45 | $1,480 |
| Amarin Pharma, Inc. | 20 | $736 |
| Novo Nordisk | 32 | $464 |
| Sanofi-aventis U.S. LLC | 23 | $451 |
| Lilly USA, LLC | 15 | $305 |
| Merck | 15 | $293 |
| GSK | 13 | $282 |
| AbbVie(2 entities) | 11 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 9 | $144 |
| AstraZeneca | 8 | $138 |
| Pfizer | 5 | $117 |
| Shield Therapeutics Inc | 5 | $107 |
| Astellas Pharma US Inc | 5 | $107 |
| Ironwood Pharmaceuticals, Inc | 5 | $93 |
| Boehringer Ingelheim | 3 | $78 |
| Bayer | 3 | $77 |
| Avanir Pharmaceuticals, Inc. | 3 | $56 |
| Vertex | 2 | $54 |
| Novartis | 2 | $51 |
| Eisai Inc. | 2 | $29 |
| Arbor Pharmaceuticals, Inc. | 1 | $23 |
| Scilex Pharmaceuticals Inc. | 1 | $21 |
| Vivus LLC | 1 | $20 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Xeris Pharmaceuticals, Inc. | 1 | $20 |
| IBSA Pharma Inc. | 1 | $19 |
| Eyevance Pharmaceuticals LLC | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Repatha$640
How this compares
$5,459 in reported general payments places this provider in the 95th percentile of 202 adolescent medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 330 | $330,500 |
| Metformin Er GastricMetformin Hcl | 224 | $298,806 |
| OzempicSemaglutide | 304 | $295,546 |
| Diclofenac Potassium | 165 | $255,513 |
| Zileuton ErZileuton | 61 | $207,534 |
| JanumetSitagliptin Phos/Metformin Hcl | 350 | $194,577 |
| VascepaIcosapent Ethyl | 748 | $190,875 |
| MeloxicamMeloxicam, Submicronized | 217 | $172,083 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 131 | $139,688 |
| JanuviaSitagliptin Phosphate | 235 | $135,395 |
| RybelsusSemaglutide | 133 | $125,180 |
| LinzessLinaclotide | 199 | $112,967 |
| MounjaroTirzepatide | 100 | $102,121 |
| Icosapent Ethyl | 730 | $87,941 |
| ProliaDenosumab | 51 | $86,582 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $305 | $432,622430 claims |
| Novo NordiskOzempic, Rybelsus | $464 | $420,726437 claims |
| MerckJanumet, Januvia | $293 | $329,971585 claims |
| AbbVieLinzess, Creon | $244 | $185,026285 claims |
| AmgenProlia | $1,480 | $86,58251 claims |
| Boehringer IngelheimJardiance, Tradjenta | $78 | $83,358146 claims |
| PfizerEliquis | $117 | $80,251138 claims |
| Astellas Pharma US IncMyrbetriq | $107 | $67,802151 claims |
| NovartisEntresto | $51 | $62,03594 claims |
| AstraZenecaFarxiga | $138 | $57,16499 claims |
| GSKTrelegy Ellipta | $282 | $53,72883 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $451 | $37,41836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 202 adolescent medicine providers in California.
Other adolescent medicine in Glendale
- Lelanie LunaGlendale$2K
- Leman YelOrange$89K
- Michelle RolandLos Angeles$22K
- Venu Prabakerla Mesa$15K
- Kanani TitchenSan Diego$8K
- David NguyenFountain Valley$6K
- Lisa LawSan Francisco$5K
- Marilou CruzDowney$5K
- Albina BenabayeStockton$5K
- Mohamad KadriLos Angeles$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.